Overslaan en naar de inhoud gaan

2020

Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®

Clinical trials

Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.

Lees meer

2019

2018

2017

Filters

  • Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren